Does meloxicam with heparin and aspirin reduce adverse outcomes in patients with acute coronary syndromes without ST-segment elevation?
In a pilot study, meloxicam added to heparin and aspirin was associated with reduced adverse outcomes in NSTE-ACS patients, though larger trials are needed.
Meloxicam with heparin and aspirin was associated with significant reductions in adverse outcomes in acute coronary syndrome patients without ST-segment elevation. Additional larger trials are required to confirm the findings of this pilot study.
Altman et al. (Tue,) studied this question.